Amgen Higher Ahead of Earnings

Facebook (FB)

JP Morgan (JPM)

AutoZone (AZO)

Yahoo (YHOO)

Apple (AAPL)

Medtronic Reports Fourth Quarter Earnings

Cracker Barrel Reports Earnings, Increases Guidance

Best ETFs For Facebook Exposure

Is Yum! Brands Closing in to Support?

Intuitive Surgical Bullish Signs

Amgen Higher Ahead of Earnings

Published on Wednesday, 25 January 2012 13:08 Written by Christopher Lynn

amgn New York, January 25th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading higher by +0.21% ahead of its quarterly earnings release. Amgen, the biotechnology company is expected to release its quarterly results on January 26^th.

Wall Street Analysts consensus calls for a profit of $1.23 a share on $3.92 billion revenue.

Amgen estimates have a range of $0.24 a share. The high estimate calls for profit of $1.34 a share and the low estimate is calling for a profit of $1.1 a share, a year ago for the quarter the company reported $1.17 a share.

Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.

Other companies on the watch on this earnings event are Novartis AG NYSE:NVS and Sanofi-Aventis NYSE:SNY.

Amgen Inc (AMGN): Today's Featured Drugs Loser - TheStreet.com
From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
Amgen Stock To Go Ex-dividend Monday (AMGN) - TheStreet.com
Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
Amgen Reaches New 52-Week High (AMGN) - TheStreet.com
Benzinga's M&A Chatter for Wednesday April 25, 2012 - Benzinga
Amgen Goes to Turkey, Loses Biotech Cred - TheStreet.com
From Earlier: Amgen to Acquire Mustafa Nevzat; Company Valued at $700M - Benzinga

Volatile market? That's when profit potential skyrockets for options traders. Now you can get up to 50 trade opportunities a week from top options experts -- plus much more -- on our exciting new site OptionsProfits. Try it FREE!